心房颤动的上游治疗研究

Advances in Upstream Treatment of Atrial Fibrillation

心房颤动(AF)是临床上常见的一种以心房快速、无序的电活动为特征的心律失常。近年来随着人口老龄化的加剧和慢性疾病生存率的提高,发病率呈逐年上升趋势,且具有较高致残率及致死率,已成为全球公共卫生领域重要的慢性疾病之一。因此,在临床上迫切需要一种有效的药物,以优化房颤的诊疗。上游治疗是个新晋的概念,2010年首次在房颤的治疗中提及,其是针对房颤发生的病因和机制提前进行干预,阻止房颤的形成和进展。本文就有关房颤上游治疗的作用机制及其研究进展作一阐述,以期为临床治疗提供参考依据。

Atrial fibrillation(AF)is a common arrhythmia in clinical practice,which is characterized by rapid and disordered electrical activity in the atria.In recent years,with the intensification of population aging and the increase in survival rate of chronic diseases,the incidence rate is increasing year by year,and it has a high disability rate and fatality rate.AF has become one of the most important chronic diseases in the global public health field.Therefore,there is an urgent need for a effective drug to optimize the diagnosis and treatment of atrial fibrillation.Upstream treatment is a new concept,and it is first mentioned in the treatment of AF in 2010.It is aimed at the cause and mechanism of AF to intervene in advance to prevent the formation and progress of AF.This article describes the mechanism of action of upstream treatment of AF and its research progress,in order to provide a reference basis for clinical treatment.